110 related articles for article (PubMed ID: 8578488)
1. Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs.
Leung LL
Thromb Haemost; 1995 Jul; 74(1):373-6. PubMed ID: 8578488
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes.
Tasset DM; Kubik MF; Steiner W
J Mol Biol; 1997 Oct; 272(5):688-98. PubMed ID: 9368651
[TBL] [Abstract][Full Text] [Related]
3. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
4. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.
Tucker TJ; Lumma WC; Mulichak AM; Chen Z; Naylor-Olsen AM; Lewis SD; Lucas R; Freidinger RM; Kuo LC
J Med Chem; 1997 Mar; 40(6):830-2. PubMed ID: 9083470
[No Abstract] [Full Text] [Related]
5. Conversion of thrombin into an anticoagulant by protein engineering.
Gibbs CS; Coutré SE; Tsiang M; Li WX; Jain AK; Dunn KE; Law VS; Mao CT; Matsumura SY; Mejza SJ
Nature; 1995 Nov; 378(6555):413-6. PubMed ID: 7477382
[TBL] [Abstract][Full Text] [Related]
6. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo.
Tsiang M; Paborsky LR; Li WX; Jain AK; Mao CT; Dunn KE; Lee DW; Matsumura SY; Matteucci MD; Coutré SE; Leung LL; Gibbs CS
Biochemistry; 1996 Dec; 35(51):16449-57. PubMed ID: 8987977
[TBL] [Abstract][Full Text] [Related]
7. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits.
Griffin LC; Tidmarsh GF; Bock LC; Toole JJ; Leung LL
Blood; 1993 Jun; 81(12):3271-6. PubMed ID: 8507864
[TBL] [Abstract][Full Text] [Related]
8. Screening of functional antidotes of RNA aptamers against bovine thrombin.
Liu X; Cao G; Ding H; Zhang D; Yang G; Liu N; Fan M; Shen B; Shao N
FEBS Lett; 2004 Mar; 562(1-3):125-8. PubMed ID: 15044012
[TBL] [Abstract][Full Text] [Related]
9. Thrombin-binding properties of thrombin aptamer derivatives.
Sumikura K; Yano K; Ikebukuro K; Karube I
Nucleic Acids Symp Ser; 1997; (37):257-8. PubMed ID: 9586097
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
Bunnage ME; Blagg J; Steele J; Owen DR; Allerton C; McElroy AB; Miller D; Ringer T; Butcher K; Beaumont K; Evans K; Gray AJ; Holland SJ; Feeder N; Moore RS; Brown DG
J Med Chem; 2007 Nov; 50(24):6095-103. PubMed ID: 17990866
[TBL] [Abstract][Full Text] [Related]
11. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
12. Surface plasmon resonance spectroscopy study of interfacial binding of thrombin to antithrombin DNA aptamers.
Tang Q; Su X; Loh KP
J Colloid Interface Sci; 2007 Nov; 315(1):99-106. PubMed ID: 17689549
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
Tucker TJ; Brady SF; Lumma WC; Lewis SD; Gardell SJ; Naylor-Olsen AM; Yan Y; Sisko JT; Stauffer KJ; Lucas BJ; Lynch JJ; Cook JJ; Stranieri MT; Holahan MA; Lyle EA; Baskin EP; Chen IW; Dancheck KB; Krueger JA; Cooper CM; Vacca JP
J Med Chem; 1998 Aug; 41(17):3210-9. PubMed ID: 9703466
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacology of site directed antithrombin agents. Implication in drug development.
Callas D; Fareed J
Thromb Haemost; 1995 Jul; 74(1):473-81. PubMed ID: 8578509
[TBL] [Abstract][Full Text] [Related]
15. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
[TBL] [Abstract][Full Text] [Related]
16. Rational engineering of activity and specificity in a serine protease.
Dang QD; Guinto ER; di Cera E
Nat Biotechnol; 1997 Feb; 15(2):146-9. PubMed ID: 9035139
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial synthesis of thrombin-binding aptamers containing iso-guanine.
Nallagatla SR; Heuberger B; Haque A; Switzer C
J Comb Chem; 2009; 11(3):364-9. PubMed ID: 19243167
[TBL] [Abstract][Full Text] [Related]
18. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation.
Li WX; Kaplan AV; Grant GW; Toole JJ; Leung LL
Blood; 1994 Feb; 83(3):677-82. PubMed ID: 8298130
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin.
Nimjee SM; Oney S; Volovyk Z; Bompiani KM; Long SB; Hoffman M; Sullenger BA
RNA; 2009 Dec; 15(12):2105-11. PubMed ID: 19846574
[TBL] [Abstract][Full Text] [Related]
20. Reconciliation of the X-ray and NMR structures of the thrombin-binding aptamer d(GGTTGGTGTGGTTGG).
Kelly JA; Feigon J; Yeates TO
J Mol Biol; 1996 Mar; 256(3):417-22. PubMed ID: 8604127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
